Tuesday - March 31, 2026

Category Archives: Pharmaceuticals & Biotech

Urothelial Carcinoma Clinical Trial Pipeline Expands as 40+ Pharma Companies Progress 50+ Novel Therapies Toward Market Entry, Finds DelveInsight | Janssen Research and Development, MedPacto

Urothelial Carcinoma – Pipeline Insight, 2026 DelveInsight’s “Urothelial Carcinoma – Pipeline Insight, 2026” report provides comprehensive insights about 40+ companies, such as Janssen Research and Development, MedPacto, AstraZeneca, QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma, RemeGen, Infinity Pharmaceuticals, … Continue reading →

Myotonic Dystrophy (DM) Clinical Trial Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | AMO Pharma, Lupin, Harmony Biosciences

Myotonic Dystrophy (DM) – Pipeline Insight, 2026 DelveInsight’s “Myotonic Dystrophy (DM) – Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies, including AMO Pharma, Lupin, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Pepgen Corporation, Aparito, … Continue reading →

Post-Traumatic Stress Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Post-Traumatic Stress Disorder Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Post-Traumatic Stress Disorder pipeline landscape. It covers the Post-Traumatic Stress Disorder Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Appears Robust With 65+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “Chronic Obstructive Pulmonary Disease Pipeline Insight 2026” report provides comprehensive insights about 65+ companies and 70+ pipeline drugs in the Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the Chronic Obstructive Pulmonary Disease pipeline drug profiles, including clinical and … Continue reading →

Gastrointestinal Stromal Tumors Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Gastrointestinal Stromal Tumors Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the Gastrointestinal Stromal Tumors pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Ischemic Stroke Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

DelveInsight’s, “Ischemic Stroke Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the Ischemic Stroke pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Hearing Loss Clinical Trial Pipeline Shows Potential with Active Contributions from 30+ Key Companies | DelveInsight

DelveInsight’s, “Hearing Loss Pipeline Insight 2026” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Hearing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Heart Failure Clinical Trial Pipeline Accelerates as 70+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Heart Failure Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Heart Failure pipeline landscape. It covers the Heart Failure pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

IgA Nephropathy Clinical Trial Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “IgA Nephropathy Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the IgA Nephropathy pipeline landscape. It covers the IgA Nephropathy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →